• Age 18-75 (≥ 18, ≤ 75), regardless of gender;

• Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;

• Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);

• According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;

• Immunohistochemical staining confirmed that Claudin 18.2 was moderately and highly expressed in tumor tissues;

• Subjects must have received the first and second line standard treatment scheme;

• The subject must not be suitable for receiving radical treatment methods, such as radical chemotherapy and radiotherapy and/or surgery/immunosuppressant at the checkpoint, or refuse surgical resection

• Within 2 weeks before cell therapy, no antibody drugs were used;

• ECOG score is 0-2;

⁃ The subjects had no contraindication for peripheral blood collection;

⁃ The expected survival period is more than 3 months.